IN8BIO, INC. — Director's Dealing 2025

May 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IN8BIO, INC. (INAB)
CIK: 0001740279
Period of Report: 2025-04-27

Reporting Person: Brandt Peter C. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-04-30	Common Stock	M	81967	$0.1844	Acquired	599571	Direct
2025-04-30	Common Stock	M	81967	$0.1844	Acquired	681538	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-04-27	Series A Warrants (right to buy)	$0.45	D	81967	Disposed	2025-10-04	Common Stock (81967)	Direct
2025-04-27	Series A Warrants (right to buy)	$0.1844	A	81967	Acquired	2025-05-02	Common Stock (81967)	Direct
2025-04-30	Series A Warrants (right to buy)	$0.1844	M	81967	Disposed	2025-05-02	Common Stock (81967)	Direct
2025-04-27	Series B Warrants (right to buy)	$1.50	D	81967	Disposed	2028-12-13	Common Stock (81967)	Direct
2025-04-27	Series B Warrants (right to buy)	$0.1844	A	81967	Acquired	2025-05-02	Common Stock (81967)	Direct
2025-04-30	Series B Warrants (right to buy)	$0.1844	M	81967	Disposed	2025-05-02	Common Stock (81967)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	105290	Indirect

Footnotes

F1: The securities are held by The Peter C. Brandt 2020-4 GRAT (the "GRAT"). The Reporting Person is the trustee of the GRAT and, as such, has voting and investment power over the shares held by the GRAT.

F2: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.

F3: Fully vested and exercisable.

F4: The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F5: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 and
expiration date of December 13, 2028. The exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.